Amal Therapeutics to publish R&D outcomes in JCI Insight

Geneva, Switzerland, April 24, 2019 – Amal Therapeutics announced today that part of its recent research findings about its self-adjuvanted chimeric protein vaccin platform, named KISIMA™, is on line on the JCI Insight website on Wednesday April 24. This publication describe the KISIMA™ efficacy in several murine tumor models (with model-, neo- and self-antigens),  its […]

AMAL Therapeutics and Natera to Partner on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine

Natera, Inc., a global leader in cell-free DNA testing, will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number of pharmaceutical trials using Natera’s SignateraTM molecular residual disease (MRD) assay as a biomarker to assess treatment response. View PDF  

SITC 2019

SITC 2019 November 6 – 10, 2019 / Washington / USA Madiha Derouazi attending

CICON 2019

CICON 2019 Sept. 25 – 28, 2019 / Paris / France Elodie Belnoue attending

BIO International Convention 2019

BIO International Convention 2019 June 3 – 6, 2019 / Philadelphia / USA Madiha Derouazi and Laurence de Schoulepnikoff attending

Swiss Biotech Day 2019

Swiss Biotech Day 2019 May 7, 2019 / Basel / Switzerland Laurence de Schoulepnikoff attending

AACR Annual Meeting 2019

AACR Annual Meeting 2019 March 29 – Apr 3, 2019 / Atlanta / USA Jean-François Mayol attending